Abstract
Introduction
Cardiovascular disease (CVD) is the leading cause of death worldwide and acts as a major barrier to sustainable human development. To address this major global health concern, in 2011, the United Nations officially recognized several noncommunicable diseases, including CVD, and set up an ambitious plan to dramatically reduce the impact of these diseases in all areas [1] .
Hypertriglyceridemia is a type of dyslipidemia characterized by an elevated serum triglycerides (TG] level and has been reported by several prospective studies and randomized controlled trials (RCTs) to be a risk factor for CVD. An increased level of circulating TG is an independent risk factor for the onset of CVD.
Hokanson and Austin reported that a fasting serum TG level of 88 mg/dL or more increases the risk of CVD development by 14% and 37% in men and women, respectively [2] . Therefore, lowering or maintaining a low level of fasting serum TG level reduces the risk of CVD. Eicosapentaenoic acid (EPA) are categorized as omega-3 fatty acids [3] .
Certain fatty acids, such as ALA and LA, cannot be synthesized in humans, and thus must be obtained in the diet. ALA, a type of omega-3 fatty acid, is converted into DHA and EPA in the body. DHA and EPA also exist naturally in some foods. LA, which is a type of omega-6 fatty acid, is converted to arachidonic acid (AA). DHA and EPA are derived from ALA by a similar biochemical pathway as AA. Omega-3 fatty acids generally lower fasting serum TG levels and very low-density lipoprotein (VLDL) levels in serum among hyperlipidemic patients. Editor: Gaetan Drouin , Laboratory of Biochemistry and Human Nutrition, France.
Data Abstraction
Various characteristics were extracted from original reports using a standardized data extraction form, including the author of the study, research year, research design, subject characteristics (sex, age, sample size), period, dose of DHA and/or EPA (mg/day), and comparison group.
Main Results
We identified 37 documents for review. Among the 37 reports used to integrate literature results, 25
revealed a decrease in fasting serum TG level due to the oral ingestion of DHA and/or EPA. Sixteen studies on subjects without disease and 21 on subjects with slightly higher fasting serum TG levels were separated and stratified analysis was conducted. Omega-6 fatty acids account for more than 10 times the omega-3 fatty acids in most American meals.
At present, there is well-known scientific agreement that omega-3 fatty acids intake should be increased and omega-6 fatty acid intake should be decreased to promote health; however, it is unknown whether the desired ratio of omega-6 and omega-3 fatty acids exists in meals, and how much omega-6 fatty acid ingestion is necessary to inhibit omega-3 production when large amounts of omega-6 are ingested.
Researchers at the Tufts Educational Policy
Committee reviewed the database of the Third National 
Eligibility Criteria
The following inclusion criteria were defined prior to the test selection process:
Participants were healthy adult men and women including those with mild hypertriglyceridemia (fasting
Intervention was defined as orally ingested DHA and/or EPA. [3] A comparison was made for placebo intake or no intake of DHA and/or EPA. [4] Results were measured according to the fasting serum TG level. [5] The test design was RCT, and quasi-RCT.
Based on these requirements, two reviewers (Y. T and H. M) independently selected studies and extracted data regarding the study characteristics and outcomes from the selected studies.
Data Abstraction
Various characteristics were extracted from original reports using a standardized data extraction form, including author of the study, research year, research design, subject characteristics (sex, age, sample size), period, dose of DHA and/or EPA (mg/day), and comparison group.
Risk of Bias Assessment
Using the Cochrane Collaboration tool to evaluate the risk of bias [42] ; low, ambiguous, or highly biased risks for five categories (random sequence generation, assignment hiding, blinded participants and personnel, incomplete outcome data, and selective outcome report) were evaluated in each study. Quality assessments for each included study were also conducted using the Cochrane Collaboration's tool for assessing risk of bias. Disagreements at any step were resolved through discussion.
Result
We found 812 reports from the database retrieval, collections, and other cited references. A total of 53 duplicated studies were excluded. We selected 193 of 759 reports that were at the primary (title and summary) screening stage. Finally, 37 reports meeting the eligibility criteria were extracted at second (full text) screening stage. Figure 1 summarizes the selection process steps. Characteristics of the 37 documents selected are listed in Table 1 together with bibliographic information. Fasting serum TG levels of control and intervention groups of the 37 reports are listed in [44, 45] . It also is presumed to increase beta-oxidation of fatty acids, and consequently, the TG are suppressed by decreasing the substrate necessary for the synthesis of TG [46] . Furthermore, omega-3 fatty acids are assumed to inhibit TG synthesis in the liver by inhibiting important enzymes involved in hepatic TG synthesis, such as phosphatidic acid phosphatase and diacylglycerol acyltransferase [47] . Moreover, it has been reported to increase the removal of fasting serum TG from circulating VLDL and chylomicron particles [48, 49] .
DHA and EPA, the major omega-3 fatty acids, have been reported to lower fasting serum TG levels; however, they are known to have different effects on LDL and high density lipoprotein (HDL) [50] [51] [52] . In a direct comparative study, in a meta-analysis comparing the effects of DHA and EPA, DHA was associated with a greater decrease in fasting serum TG and a greater increase in LDL than EPA. DHA also increased HDL compared to placebo, but EPA did not [51] . Further studies are needed to clarify the mechanisms and significance of these differences [50] [51] [52] . Research on most omega-3 fatty acids is directed toward DHA and EPA; however, recently omega-3 docosapentaenoic acid (DPA) also has been drawing attention. The level of DPA in serum has is individually associated with a reduction in the risk of myocardial infarction and coronary heart disease [53, 54] . When the DPA level in the serum decreases, the risk of peripheral arterial disease such as vascular plaque formation increases [55, 56] . DPA has a stronger inhibitory action on platelet aggregation than DHA and EPA [57] . Like DHA and EPA, DPA has been reported to decrease the expression of inflammatory genes [58] . As the fasting serum TG-lowering mechanism of action of long-chain omega-3 fatty acids differs from that of other lipid-lowering drugs, such as statins, they can potentially provide complementary benefits on the lipid profile when administered in combination [35] . This is supported by a study examining the synergistic effect of the lowering action of fasting serum TG by omega-3 fatty acids in addition to statin therapy [59] [60] [61] [62] .
This research had certain limitations. There was a possibility that sampling bias existed in the studies used and there was language bias due to the database search using only English and Japanese keywords; however, all reports adopted in this study were peer-reviewed RCTs, the quality of each research was thought to be high, the bias risk was roughly not a problem, and the quality of scientific evidence could be sufficiently judged. In this systematic review, meta-analysis could not be performed due to several reasons, mainly clinical heterogeneity; however, the evidence level of an individual RCT is considered to be sufficiently high, that is, it can be said that DHA and/or EPA intake can reduce and maintain a suitable level of fasting serum TG.
In modern society, the importance of functional foods is increasing in terms of medical economics; however, it will be necessary to accumulate evidence from interventional studies targeting healthy people and perform meta-analysis.
Authors' Conclusions
The studies involving dietary interventions assessed in our review and results from healthy participants revealed that consuming 133-10,440 mg of DHA and/or EPA produces fasting serum TG lowering effects in healthy or slightly higher fasting serum TG level individuals. 
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